- Home
- HOMB vs NUVL Comparison
HOMB vs NUVL Comparison
Compare HOMB & NUVL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HOMB
- NUVL
- Stock Information
- Founded
- HOMB 1998
- NUVL 2017
- Country
- HOMB United States
- NUVL United States
- Employees
- HOMB N/A
- NUVL N/A
- Industry
- HOMB Major Banks
- NUVL Biotechnology: Pharmaceutical Preparations
- Sector
- HOMB Finance
- NUVL Health Care
- Exchange
- HOMB Nasdaq
- NUVL Nasdaq
- Market Cap
- HOMB 5.5B
- NUVL 5.6B
- IPO Year
- HOMB 2006
- NUVL 2021
- Fundamental
- Price
- HOMB $28.13
- NUVL $73.05
- Analyst Decision
- HOMB Buy
- NUVL Strong Buy
- Analyst Count
- HOMB 4
- NUVL 10
- Target Price
- HOMB $31.25
- NUVL $113.10
- AVG Volume (30 Days)
- HOMB 1.2M
- NUVL 583.7K
- Earning Date
- HOMB 04-16-2025
- NUVL 05-08-2025
- Dividend Yield
- HOMB 2.77%
- NUVL N/A
- EPS Growth
- HOMB 3.65
- NUVL N/A
- EPS
- HOMB 2.01
- NUVL N/A
- Revenue
- HOMB $969,021,000.00
- NUVL N/A
- Revenue This Year
- HOMB $9.80
- NUVL N/A
- Revenue Next Year
- HOMB $3.57
- NUVL N/A
- P/E Ratio
- HOMB $14.00
- NUVL N/A
- Revenue Growth
- HOMB N/A
- NUVL N/A
- 52 Week Low
- HOMB $22.38
- NUVL $61.80
- 52 Week High
- HOMB $32.91
- NUVL $113.51
- Technical
- Relative Strength Index (RSI)
- HOMB 42.17
- NUVL 41.46
- Support Level
- HOMB $27.69
- NUVL $71.95
- Resistance Level
- HOMB $29.00
- NUVL $77.93
- Average True Range (ATR)
- HOMB 0.56
- NUVL 3.11
- MACD
- HOMB 0.05
- NUVL 0.11
- Stochastic Oscillator
- HOMB 40.00
- NUVL 58.12
About HOMB Home BancShares Inc.
Home BancShares Inc is a bank holding company that operates through its wholly owned community bank subsidiary, Centennial Bank. The bank provides a broad range of commercial and retail banking, as well as related financial services, to a diverse customer base. Its customer base includes businesses, real estate developers and investors, individuals, and municipalities. The company's loan portfolio, while diversified, is typically between half and two thirds in commercial real estate loans. The company's plan emphasizes growth, both through strategic acquisitions and organically within its existing markets. The bank also emphasizes attracting experienced bankers, credit quality, and a solid balance sheet. The bank's main source of net revenue is net interest income.
About NUVL Nuvalent Inc.
Nuvalent Inc is a clinical stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically proven kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.